Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration
about
Advances and challenges in malaria vaccine developmentCross-species malaria immunity induced by chemically attenuated parasites.Age-related differences in naturally acquired T cell memory to Plasmodium falciparum merozoite surface protein 1Lessons learnt from the first controlled human malaria infection study conducted in Nairobi, KenyaIn vitro antimalarial activity and drug interactions of fenofibric acidTailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?Malaria treatment with atovaquone-proguanil in malaria-immune adults: implications for malaria intervention trials and for pre-exposure prophylaxis of malaria.Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity.Progress and prospects for blood-stage malaria vaccinesClinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki.Atovaquone and ELQ-300 Combination Therapy as a Novel Dual-Site Cytochrome bc1 Inhibition Strategy for Malaria.Statins as potential antimalarial drugs: low relative potency and lack of synergy with conventional antimalarial drugsHuman T cell recognition of the blood stage antigen Plasmodium hypoxanthine guanine xanthine phosphoribosyl transferase (HGXPRT) in acute malaria.Approaches to malaria vaccine development using the retrospectroscope.Interferon-γ--central mediator of protective immune responses against the pre-erythrocytic and blood stage of malaria.Controlled human blood stage malaria infection: current status and potential applications.Examining cellular immune responses to inform development of a blood-stage malaria vaccine.Chemical Attenuation in the Development of a Whole-Organism Malaria Vaccine.Substantially reduced pre-patent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum.Prolonged protection provided by a single dose of atovaquone-proguanil for the chemoprophylaxis of Plasmodium falciparum malaria in a human challenge model.Controlled Human Malaria Infection: Applications, Advances and Challenges.Vaccine candidates for malaria: what's new?
P2860
Q21032463-B4B09CDD-494E-4288-86BC-D60D9BCD8076Q33570804-9F1D58D1-AFE9-4305-AC35-DFDCBEC913D8Q34026347-1546C358-7049-475F-BF1A-33F4CE2BE4A4Q35559418-68C33D74-86A4-4F0E-8859-01A4578CCAA0Q36018677-24059A01-331C-4FAB-9D86-199156E40BA5Q36114395-15E9576A-31C1-4ED8-B6B6-1D405B407124Q36391845-98FF89E8-4333-4B9C-8F38-C83A65A4D948Q36538784-3EFAB4B7-1C2D-488A-BE33-EF88EA623694Q36835495-C1C439F4-863C-4046-BFAF-5FA9FBE886FAQ37025030-7ACC801A-AEF3-410D-9A09-706D3E7AE842Q37052790-6705BD57-F594-4793-9E09-50FE0B68FBDDQ37120173-555BDB5A-BEEA-4359-90FF-14CD26DE8A0DQ37190868-93116EBE-E241-4D5B-8881-A26689ECCE2EQ37236984-B1B0B65A-0127-432D-8D7C-B234CAC07C97Q37274832-1F3E962E-4C0F-4B82-8316-64812746DBB6Q37770828-63F50092-3C14-4FA5-8C8F-4902E0F33F49Q38001604-82B5B634-E9D1-4F01-84A4-6A805C2AEC16Q38689861-747DC782-DC56-495A-AB7E-7063DF1B3423Q39259814-F5A836FB-38E8-4D7D-9CDE-1F5693F3FA42Q42127731-4EC2BD4B-096B-40B1-99C3-58B62E4F24EAQ44160872-9D0C0C53-762D-4809-AA57-B3F6260F8998Q44168331-721CB01C-914B-457E-A585-11639CA35A13Q47935989-2B4C35A2-82CF-4FE1-AE98-D612B11FB948
P2860
Lengthy antimalarial activity of atovaquone in human plasma following atovaquone-proguanil administration
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Lengthy antimalarial activity ...... quone-proguanil administration
@en
Lengthy antimalarial activity ...... quone-proguanil administration
@nl
type
label
Lengthy antimalarial activity ...... quone-proguanil administration
@en
Lengthy antimalarial activity ...... quone-proguanil administration
@nl
prefLabel
Lengthy antimalarial activity ...... quone-proguanil administration
@en
Lengthy antimalarial activity ...... quone-proguanil administration
@nl
P2093
P2860
P1476
Lengthy antimalarial activity ...... quone-proguanil administration
@en
P2093
P2860
P304
P356
10.1128/AAC.49.10.4421-4422.2005
P407
P577
2005-10-01T00:00:00Z